{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T19:10:28Z","timestamp":1783019428225,"version":"3.54.6"},"reference-count":42,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T00:00:00Z","timestamp":1722297600000},"content-version":"unspecified","delay-in-days":211,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Program of West China","award":["ZYJ21029"],"award-info":[{"award-number":["ZYJ21029"]}]},{"name":"Key R&D Program of China","award":["2022YFC2009900"],"award-info":[{"award-number":["2022YFC2009900"]}]},{"name":"Key R&D Program of China","award":["2022YFC2009906"],"award-info":[{"award-number":["2022YFC2009906"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Ment Health"],"accepted":{"date-parts":[[2024,7,15]]},"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Behavioural and psychological symptoms of dementia (BPSD) are highly prevalent in people living with dementia. Second-generation antipsychotics (SGAs) are commonly used to treat BPSD, but their comparative efficacy and acceptability are unknown.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>The standard mean difference (SMD) was used to pool the fixed effects of continuous outcomes. We calculated ORs with corresponding 95% credible intervals (CI) for the categorical variable. Efficacy was defined as the scores improved on the standardised scales. Acceptability was defined as the all-cause dropout rate. Tolerability was defined as the discontinuation rate due to adverse effects (AEs). The relative treatment rankings were reported with the surface under the cumulative curve. The AE outcomes included mortality, cerebrovascular adverse events (CVAEs), falls, sedation, extrapyramidal symptoms and urinary symptoms.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Twenty randomised controlled trials with a total of 6374 individuals containing 5 types of SGAs (quetiapine, olanzapine, risperidone, brexpiprazole and aripiprazole) with intervention lengths ranging from 6 weeks to 36 weeks were included in this network meta-analysis. For the efficacy outcome, compared with the placebo, brexpiprazole (SMD=\u22121.77, 95%\u2009CI \u22122.80 to \u22120.74) was more efficacious, and brexpiprazole was better than quetiapine, olanzapine and aripiprazole. Regarding acceptability, only aripiprazole (OR=0.72, 95% CI 0.54 to 0.96) was better than the placebo, and aripiprazole was also better than brexpiprazole (OR=0.61, 95% CI 0.37 to 0.99). In terms of tolerability, olanzapine was worse than placebo (OR=6.02, 95% CI 2.87 to 12.66), risperidone (OR=3.67, 95% CI 1.66 to 8.11) and quetiapine (OR=3.71, 95% CI 1.46 to 9.42), while aripiprazole was better than olanzapine (OR=0.25, 95% CI 0.08 to 0.78). Quetiapine presented good safety in CVAE. Brexpiprazole has better safety in terms of falls and showed related safety in sedation among included SGAs.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Brexpiprazole showing great efficacy in the treatment of BPSD, with aripiprazole showing the highest acceptability and olanzapine showing the worst tolerability. The results of this study may be used to guide decision-making.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjment-2024-301019","type":"journal-article","created":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T22:40:30Z","timestamp":1722379230000},"page":"e301019","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":20,"title":["Efficacy, acceptability and tolerability of second-generation antipsychotics for behavioural and psychological symptoms of dementia: a systematic review and network meta-analysis"],"prefix":"10.1136","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4083-8257","authenticated-orcid":false,"given":"Wenqi","family":"L\u00fc","sequence":"first","affiliation":[{"name":"Department of Psychiatry, West China Hospital of Sichuan University, Chengdu, Sichuan Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangzhou","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Neurology, West China Hospital of Sichuan University, Chengdu, Sichuan Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuwei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, West China Hospital of Sichuan University, Chengdu, Sichuan Province, China"},{"name":"Department of Geriatrics, Chengdu Second People\u2019s Hospital, Chengdu, Sichuan Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiance","family":"He","sequence":"additional","affiliation":[{"name":"Department of Geriatric Psychiatry, The Fourth People\u2019s Hospital of Chengdu, Chengdu, Sichuan Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongbo","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Radiology, West China Hospital of Sichuan University, Chengdu, Sichuan Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huifang","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Geriatric Psychiatry, The Fourth People\u2019s Hospital of Chengdu, Chengdu, Sichuan Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, West China Hospital of Sichuan University, Chengdu, Sichuan Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, West China Hospital of Sichuan University, Chengdu, Sichuan Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihong","family":"Kuang","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, West China Hospital of Sichuan University, Chengdu, Sichuan Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,7,30]]},"reference":[{"key":"2025082701134200000_27.1.e301019.1","doi-asserted-by":"crossref","first-page":"653","DOI":"10.3233\/JAD-180375","article-title":"Secular trends in dementia prevalence and incidence worldwide: a systematic review","volume":"66","author":"Stephan","year":"2018","journal-title":"J Alzheimers Dis"},{"key":"2025082701134200000_27.1.e301019.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31363-6"},{"key":"2025082701134200000_27.1.e301019.3","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.12730"},{"key":"2025082701134200000_27.1.e301019.4","doi-asserted-by":"publisher","DOI":"10.1177\/2040622316658463"},{"key":"2025082701134200000_27.1.e301019.5","first-page":"5","article-title":"Using antipsychotic agents in older patients","volume":"65 Suppl 2","author":"Alexopoulos","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"2025082701134200000_27.1.e301019.6","doi-asserted-by":"crossref","DOI":"10.3390\/ph14030246","article-title":"Behavioral and psychological symptoms in dementia (BPSD) and the use of antipsychotics","volume":"14","author":"Calsolaro","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"key":"2025082701134200000_27.1.e301019.7","doi-asserted-by":"crossref","first-page":"349","DOI":"10.2165\/00002512-199303040-00005","article-title":"Drug-induced cognitive impairment. defining the problem and finding solutions","volume":"3","author":"Bowen","year":"1993","journal-title":"Drugs Aging"},{"key":"2025082701134200000_27.1.e301019.8","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.93"},{"key":"2025082701134200000_27.1.e301019.9","doi-asserted-by":"crossref","first-page":"725","DOI":"10.3233\/JAD-161247","article-title":"Efficacy of antidepressants for depression in alzheimer\u2019s disease: systematic review and meta-analysis","volume":"58","author":"Orgeta","year":"2017","journal-title":"J Alzheimers Dis"},{"key":"2025082701134200000_27.1.e301019.10","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2014-308112"},{"key":"2025082701134200000_27.1.e301019.11","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.0828","article-title":"Assessment of reported comparative effectiveness and safety of atypical antipsychotics in the treatment of behavioral and psychological symptoms of dementia: a network meta-analysis","volume":"2","author":"Yunusa","year":"2019","journal-title":"JAMA Netw Open"},{"key":"2025082701134200000_27.1.e301019.12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71"},{"key":"2025082701134200000_27.1.e301019.13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60046-5"},{"key":"2025082701134200000_27.1.e301019.14","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1186"},{"key":"2025082701134200000_27.1.e301019.15","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/jrsm.1044","article-title":"Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies","volume":"3","author":"Higgins","year":"2012","journal-title":"Res Synth Methods"},{"key":"2025082701134200000_27.1.e301019.16","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d5928","article-title":"The cochrane collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"2025082701134200000_27.1.e301019.17","doi-asserted-by":"crossref","DOI":"10.1186\/1741-7015-11-159","article-title":"Is network meta-analysis as valid as standard pairwise meta-analysis? It all depends on the distribution of effect modifiers","volume":"11","author":"Jansen","year":"2013","journal-title":"BMC Med"},{"key":"2025082701134200000_27.1.e301019.18","doi-asserted-by":"crossref","first-page":"e588","DOI":"10.1093\/pubmed\/fdac036","article-title":"Strengthening systematic reviews in public health: guidance in the cochrane handbook for systematic reviews of interventions, 2nd edition","volume":"44","author":"Cumpston","year":"2022","journal-title":"J Public Health (Oxf)"},{"key":"2025082701134200000_27.1.e301019.19","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1001\/jamaneurol.2023.3810","article-title":"Brexpiprazole for the treatment of agitation in alzheimer dementia: a randomized clinical trial","volume":"80","author":"Lee","year":"2023","journal-title":"JAMA Neurol"},{"key":"2025082701134200000_27.1.e301019.20","doi-asserted-by":"publisher","DOI":"10.1097\/01.jcp.0000178415.22309.8f"},{"key":"2025082701134200000_27.1.e301019.21","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajgp.13.8.722"},{"key":"2025082701134200000_27.1.e301019.22","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v60n0207"},{"key":"2025082701134200000_27.1.e301019.23","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jagp.2019.09.009","article-title":"Efficacy and safety of brexpiprazole for the treatment of agitation in alzheimer\u2019s dementia: two 12-week, randomized, double-blind, placebo-controlled trials","volume":"28","author":"Grossberg","year":"2020","journal-title":"Am J Geriatr Psychiatry"},{"key":"2025082701134200000_27.1.e301019.24","doi-asserted-by":"publisher","DOI":"10.1002\/gps.1032"},{"key":"2025082701134200000_27.1.e301019.25","doi-asserted-by":"publisher","DOI":"10.2174\/156720507779939805"},{"key":"2025082701134200000_27.1.e301019.26","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v64n0205"},{"key":"2025082701134200000_27.1.e301019.27","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1212\/WNL.53.5.946","article-title":"A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia","volume":"53","author":"De Deyn","year":"1999","journal-title":"Neurology (ECronicon)"},{"key":"2025082701134200000_27.1.e301019.28","doi-asserted-by":"publisher","DOI":"10.1002\/gps.1409"},{"key":"2025082701134200000_27.1.e301019.29","doi-asserted-by":"publisher","DOI":"10.1097\/01.JGP.0000194643.63245.8c"},{"key":"2025082701134200000_27.1.e301019.30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa061240"},{"key":"2025082701134200000_27.1.e301019.31","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.57.10.968"},{"key":"2025082701134200000_27.1.e301019.32","doi-asserted-by":"publisher","DOI":"10.1097\/01.JGP.0000196628.12010.35"},{"key":"2025082701134200000_27.1.e301019.33","doi-asserted-by":"publisher","DOI":"10.1097\/JGP.0b013e318165db77"},{"key":"2025082701134200000_27.1.e301019.34","doi-asserted-by":"publisher","DOI":"10.1002\/gps.1892"},{"key":"2025082701134200000_27.1.e301019.35","doi-asserted-by":"publisher","DOI":"10.1097\/JGP.0b013e3181557b47"},{"key":"2025082701134200000_27.1.e301019.36","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1212\/01.wnl.0000260060.60870.89","article-title":"Quetiapine for agitation or psychosis in patients with dementia and parkinsonism","volume":"68","author":"Kurlan","year":"2007","journal-title":"Neurology (ECronicon)"},{"key":"2025082701134200000_27.1.e301019.37","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.38369.459988.8F"},{"key":"2025082701134200000_27.1.e301019.38","doi-asserted-by":"publisher","DOI":"10.1016\/j.eurpsy.2007.03.001"},{"key":"2025082701134200000_27.1.e301019.39","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1001\/jamaneurol.2023.3967","article-title":"Brexpiprazole for the treatment of agitation and aggression in alzheimer disease","volume":"80","author":"Ballard","year":"2023","journal-title":"JAMA Neurol"},{"key":"2025082701134200000_27.1.e301019.40","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2014-007382","article-title":"Monetary costs of agitation in older adults with alzheimer\u2019s disease in the UK: prospective cohort study","volume":"5","author":"Morris","year":"2015","journal-title":"BMJ Open"},{"key":"2025082701134200000_27.1.e301019.41","doi-asserted-by":"publisher","DOI":"10.1097\/YCO.0b013e32835f414b"},{"key":"2025082701134200000_27.1.e301019.42","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1056\/NEJMoa2034634","article-title":"Trial of pimavanserin in dementia-related psychosis","volume":"385","author":"Tariot","year":"2021","journal-title":"N Engl J Med"}],"container-title":["BMJ Mental Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjment-2024-301019","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T08:13:48Z","timestamp":1756282428000},"score":1,"resource":{"primary":{"URL":"https:\/\/mentalhealth.bmj.com\/lookup\/doi\/10.1136\/bmjment-2024-301019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,7,30]]},"published-print":{"date-parts":[[2024,1]]}},"alternative-id":["10.1136\/bmjment-2024-301019"],"URL":"https:\/\/doi.org\/10.1136\/bmjment-2024-301019","relation":{},"ISSN":["2755-9734"],"issn-type":[{"value":"2755-9734","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1]]}}}